Advertisement

Journal of Pharmacokinetics and Biopharmaceutics

, Volume 24, Issue 5, pp 449–459 | Cite as

Overview of enzymes of drug metabolism

  • Urs A. Meyer
Article

Abstract

Most pharmacologically active molecules are lipophilic and remain un-ionized or only partially ionized at physiological pH. Biotransformation means that a lipid-soluble xenobiotic or endobiotic compound is enzymatically transformed into polar, water-soluble, and excretable metabolites. The major organ for drug biotransformation is the liver. The metabolic products often are less active than the parent drug or inactive. However, some biotransformation products (metabolites) may have enhanced activity or toxic effects. Thus biotransformation may include both “detoxication” and “toxication” processes. One of the major enzyme systems that determines the organism's capability of dealing with drugs and chemicals is represented by the cytochrome P450 monooxygenases. Studies in the last 15 years have provided evidence that cytochrome P450 occurs in many different forms or “isozymes” which differ in spectral, chemical, and immunological properties and have different substrate affinities. These isozymes also differ in their regulation and tissue distribution. Recombinant DNA studies indicate that between 40 and 60 structural genes code for different cytochrome P450 isozymes in a single organism. Other enzyme systems include dehydrogenases, oxidases, esterases, reductases, and a number of conjugating enzyme systems including glucuronosyltransferases, sulfotransferases, glutathione S-transferases, etc. Environmental and genetic factors cause interindividual and intraindividual differences in drug metabolism and may alter the balance between toxification and detoxification reactions. Genetic polymorphisms lead to subpopulations of patients with decreased, absent, or even increased activities of certain reactions (e.g., CYP2D6, CYP2C19, N-acetyltransferase polymorphism). Environmental factors such as other drugs, steroids, dietary factors, alcohol, and cigarette smoke can induce or inhibit drug-metabolizing enzymes and cause intraindividual variation.

Key Words

drug metabolism interindividual variation cytochrome P450 induction genetic polymorphism in vitro prediction 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    P. R. Ortiz de Montellano (ed.).Cytochrome P450. Structure, Mechanism, and Biochemistry, Plenum Press, New York, 1995.Google Scholar
  2. 2.
    M. Pirmohamed, N. R. Kitteringham, and B. K. Park. The role of active metabolites in drug toxicity.Drug Safety 11:114–144 (1994).PubMedCrossRefGoogle Scholar
  3. 3.
    D. R. Nelson, T. Kamataki, D. J. Waxman, F. P. Guengerich, R. W. Estabrook, R. Feyereisen, F. J. Gonzalez, M. J. Coon, I. C. Gunsalus, O. Gotoh, K. Okuda, and D. W. Nebert. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature.DNA Cell Biol. 12:1–51 (1993).PubMedCrossRefGoogle Scholar
  4. 4.
    U. A. Meyer, R. C. Skoda, U. M. Zanger, M. Heim, and F. Broly. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. In W. Kalow (ed.),Pharmacogenetics of Drug Metabolism, Pergamon, New York, 1992, pp. 609–623.Google Scholar
  5. 5.
    U. A. Meyer. Commentary. Pharmacogenetics: The slow, the rapid, and the ultrarapid.Proc. Natl. Acad. Sci. U.S. 91:1983–1984 (1994).CrossRefGoogle Scholar
  6. 6.
    W. Kalow, H. W. Goedde, and D. P. Agarwal.Ethnic Differences in Reactions to Drugs and Xenobiotics, AR Liss, New York, 1986.Google Scholar
  7. 7.
    M. Heim and U. A. Meyer. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification.Lancet 336:529–532 (1990).PubMedCrossRefGoogle Scholar
  8. 8.
    F. Broly, D. Marez, N. Sabbagh, M. Legrand, S. Millecamps, J.-M. Lo Guidice, P. Boone, and U. A. Meyer. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.Pharmacogenetics 5:373–384 (1995).PubMedCrossRefGoogle Scholar
  9. 9.
    S. M. F. De Morais, G. R. Wilkinson, J. Blaisdell, K. Nakamura, U. A. Meyer, and J. A. Goldstein. The major genetic defect responsible for the polymorphism ofS-mephenytoin metabolism in humans.J. Biol. Chem. 269:15419–15422 (1994).PubMedGoogle Scholar
  10. 10.
    S. M. F. De Morais, G. R. Wilkinson, J. Blaisdell, U. A. Meyer, K. Nakamura, and J. A. Goldstein. Identification of new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.Mol. Pharmacol. 46:594–598 (1994).PubMedGoogle Scholar
  11. 11.
    U. A. Meyer and U. M. Zanger. Molecular mechanisms of genetic polymorphisms of drug metabolism.Annu. Rev. Pharmacol. Toxicol. 37: 269–296 (1997).PubMedCrossRefGoogle Scholar
  12. 12.
    A. B. Okey. Enzyme induction in the cytochrome P450 system. In W. Kalow (ed.),Pharmacogenetics of Drug Metabolism, Pergamon, New York, 1992, pp. 549–608.Google Scholar
  13. 13.
    D. J. Waxman and L. Azaroff. Phenobarbital induction of cytochrome P450 gene expression.Biochem. J. 281:577–592 (1992).PubMedCentralPubMedGoogle Scholar
  14. 14.
    J. P. Whitlock, Jr. Mechanistic aspects of dioxin action.Chem. Res. Toxicol. 6:754–763 (1993).PubMedCrossRefGoogle Scholar
  15. 15.
    J. George, M. Murray, K. Byth, and G. C. Farrell. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease.Hepatology 21:120–128 (1995).PubMedGoogle Scholar
  16. 16.
    P. J. Meier, H. K. Mueller, B. Dick, and U. A. Meyer, Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.Gastroenterology 85:682–692 (1993).Google Scholar
  17. 17.
    T. Kronbach, V. Fischer, and U. A. Meyer. Cyclosporine metabolism in human liver: Identification of a cytochrome P450 of the P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.Clin. Pharmacol. Ther. 43:630–635 (1988).PubMedCrossRefGoogle Scholar
  18. 18.
    T. Kronbach, D. Mathys, M. Umeno, F. J. Gonzalez and U. A. Meyer. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.Mol. Pharmacol. 36:89–96 (1989).PubMedGoogle Scholar
  19. 19.
    T. Andersson, J. O. Miners, M. E. Veronese, W. Tassaneeyakul, W. Tassaneeyakul, U. A. Meyer, and D. J. Birkett. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism.Br. J. Clin. Pharmacol. 36:521–530 (1993).PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    F. P. Guengerich, D. Müller-Enoch, and I. A. Blair. Oxidation of quinidine by human liver cytochrome P-450.Mol. Pharmacol. 30:287–295 (1986).PubMedGoogle Scholar
  21. 21.
    R. Fonne-Pfister and U. A. Meyer. Xenobiotic and endobiotic inhibitors of cytochrome P450db1 function, the target of the debrisoquine/sparteine type polymorphism.Biochem. Pharmacol. 37:3829–3835 (1988).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • Urs A. Meyer
    • 1
  1. 1.Department of PharmacologyBiozentrum of the University of BaselBaselSwitzerland

Personalised recommendations